



Amicus Therapeutics Announces Participation at World Muscle Society 2022

October 11, 2022

PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- [Amicus Therapeutics](#) (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included at the [27th International Hybrid Annual Congress of the World Muscle Society](#), being held October 11-15, 2022 both virtually and in Halifax, Canada.

Poster Presentations:

Abstract Title: *Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label phase I/II study (ATB200-02)* (Poster #FP.17)

- **Presenter:** Benedikt Schoser, MD, Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
- **Flash Poster Presentation:** Metabolic Myopathies – Wednesday, October 12, 4:05-4:10 p.m. ADT
 - **Location:** Ballroom Salon
- **Poster Session:** Metabolic Myopathies – Wednesday, October 12, 4:00-5:30 p.m. ADT
 - **Location:** Ballroom B1-B2

Abstract Title: *Living with Pompe disease in the UK: characterising the patient journey; burden on physical and emotional quality of life; and impact of COVID-19* (Poster #VP.32)

- **Presenter:** Allan Muir, Chair of the Board of Trustees, Pompe Support Network, Petersfield, U.K.
- **Poster Session:** Metabolic Myopathies – Wednesday, October 12, 4:00-5:30 p.m. ADT
- **Location:** Virtual Platform

Abstract Title: *Quantification of the burden, unmet needs, management, and COVID-19 impact of living with Pompe disease in the UK: results of an online patient survey* (Poster #VP.33)

- **Presenter:** Val Buxton, Association for Glycogen Storage Disease (UK), Oldbury, U.K.
- **Poster Session:** Metabolic Myopathies – Wednesday, October 12, 4:00-5:30 p.m. ADT
- **Location:** Virtual Platform

Abstract Title: *Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: a network meta-analysis with patient-level and aggregate data* (Poster #LSVP.19)

- **Presenter:** Jeff Castelli, PhD, Amicus Therapeutics Inc., Philadelphia, PA, U.S.A.
- **Poster Session:** Poster Session 4 – Friday, October 14, 5:00-6:00 p.m. ADT
- **Location:** Virtual Platform

The posters will be made available on the Amicus [website](#) following their respective presentations at the congress.

For more information on the World Muscle Society 2022 Annual Congress, please visit www.wms2022.com.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at www.amicusrx.com, and follow us on [Twitter](#) and [LinkedIn](#).

CONTACTS:

Investors:

Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:

Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com

(609) 662-5079

FOLD-G